-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3469 Comparison of the Efficacy and Adverse Effects of Recipient-Derived Versus Donor-Derived CAR-T Cell Therapy for Post-Transplant Relapse in B-ALL

Program: Oral and Poster Abstracts
Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster II
Hematology Disease Topics & Pathways:
Research, Clinical Research, Real-world evidence
Sunday, December 8, 2024, 6:00 PM-8:00 PM

Lichao Liu1*, Ruihao Huang, PhD student2*, Yongxian Hu3*, Sanfang Tu4*, Na Wang5*, Hai Yi, MD6*, Qiuying Gao7*, Jian Zhou, MD, PhD8*, Xiaoqi Wang, MD2*, Cheng Zhang, MD, PhD1* and Xi Zhang, PhD9

1Xinqiao Hospital, Army Medical University, Chongqing, China
2Army medical University affiliated Xinqiao Hospital, Chongqing, China
3Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
4Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou, China
5Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CHN
6Department of Hematology, The General Hospital of Western Theater Command, Chengdu, China
7Department of Hematology, Shaanxi Provincial People's Hospital, Xi'an, China
8Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
9Medical Center of Hematology, Xinqiao Hospital of Army Medical University, State Key Laboratory of Trauma and Chemical Poisoning, Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing, China

Background

Chimeric Antigen Receptor T (CAR-T) cells have been demonstrated to be an effective treatment for relapsed acute B-cell lymphoblastic leukemia (B-ALL) following allogeneic hematopoietic stem cell transplantation (allo-HSCT). T cells for CAR-T therapy can be derived from the patient's own peripheral blood (recipient) or from the donor's peripheral blood. Despite having identical genomes, the different maturation environments of these T cells can lead to functional differences. This study aims to compare the clinical outcomes of CAR-T cells derived from these two sources.

Methods

This multicenter, retrospective cohort study collected clinical data from 36 patients who experienced B-ALL relapse after allo-HSCT and received CD19 CAR-T cell therapy between January 2016 and October 2023 across seven centers. The primary endpoint was the complete remission (CR)/CR with incomplete hematologic recovery (CRi) rate at 28 days post-CAR-T cell infusion. Secondary endpoints included the 2-year overall survival (OS) rate, 2-year event-free survival (EFS) rate, incidence of graft-versus-host disease (GVHD), cytokine release syndrome (CRS), and CAR-T cell-related encephalopathy syndrome (CRES).

Results

Retrospective analysis was performed on 36 patients: 12 in the recipient group and 24 in the donor group. The recipient and donor groups showed no significant differences in CR/CRi rates (83.33% vs. 100%, P=0.105), 2-year EFS rates (50.8% vs. 51.6%, P=0.617), and 2-year OS rates (49.5% vs. 63.6%, P=0.215). Additionally, the incidence of GVHD, CRS, and CRES did not significantly differ between the two groups. Further analysis within the donor group revealed 12 matched sibling donors (MSD) and 12 haploidentical donors (HID). The 2-year EFS rate was significantly higher in the HID group compared to the MSD group (75.0% vs. 30.7%, P=0.043), while no significant differences were observed in CR/CRi rates, 2-year OS, and the incidence of GVHD, CRS, and CRES between these subgroups.

Conclusion

Both recipient-derived and donor-derived CD19 CAR-T cell therapies are effective treatment options for B-ALL relapsed post-allo-HSCT. Haploidentical donor-derived CAR-T cells offer a longer EFS and may be considered the optimal choice.

Disclosures: No relevant conflicts of interest to declare.

See more of: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster II
See more of: Oral and Poster Abstracts
<< Previous Abstract | Next Abstract >>
*signifies non-member of ASH